Key Takeaways
  • Semax is not approved by the FDA for any medical use in the United States, and the October 2026 HHS policy did not change that.
  • On October 28, 2026, HHS issued an enforcement discretion policy, published in the Federal Register on October 30, 2026 under docket HHS-OASH-2026-0496, covering six peptide bulk drug substances including Semax.
  • HHS states it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility, or a licensed physician compounding Semax free base for intranasal use, but only if every condition in the policy is satisfied.
  • Those conditions include a valid prescription for an identified individual patient, a single active ingredient per product (so no blends), an FDA registered and CGMP compliant original manufacturer whose physical location appears on the certificate of analysis, a certificate matching the attributes set out in Appendix B, MedWatch reporting of serious adverse events and product quality problems, and the label statement "This is a compounded drug product. Not for resale."
  • The only device the policy contemplates being co-packaged with or containing the compounded product is a 510(k) cleared syringe, which on a plain reading leaves pens and auto-injectors outside the policy.
  • This is neither an approval nor an entry on the 503A bulk drug substances list. It is explicitly temporary and non-binding, HHS reserves the right to revisit it if a safety signal or product quality issue emerges, and FDA's own Center for Drug Evaluation and Research had recommended against listing these peptides.
  • The policy does not cover research use only products, does not cover 503B outsourcing facilities, and changes nothing outside the United States.

Is Semax approved by the FDA?

No. Semax is not an FDA approved drug in the United States. There is no approved new drug application and no approved generic for it, and it does not appear on the list of bulk drug substances that compounders may use under section 503A of the Federal Food, Drug, and Cosmetic Act. Any product containing Semax that reaches a patient in the United States is, in regulatory terms, an unapproved drug.

What changed in late 2026 is narrower than approval, and the distinction matters. On October 28, 2026, the Department of Health and Human Services issued a document titled HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. In it, HHS states that it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility, or a licensed physician that compounds a drug product using one of six named peptide bulk drug substances, provided that every circumstance described in the policy is met. Semax is one of the six.

Enforcement discretion is a statement about what an agency intends to do, not a statement about what the law permits. The compounded product remains an unapproved drug. The policy itself says it has no formal effect of law and is not binding on HHS or on the public. A pharmacy operating inside the conditions is not holding a marketing authorization, and a patient receiving such a product is not receiving an approved medicine.

This page covers only the United States prescription and pharmacy compounding question. For the general background on the molecule itself, see the Semax guide. For how legal status differs across jurisdictions, see are peptides legal. This article is educational and is not medical advice. Consult a licensed healthcare professional about any individual situation.

What did HHS announce in October 2026?

The policy document is dated October 28, 2026. Notice of it was published in the Federal Register on October 30, 2026 (Volume 91, Number 209), under document number 2026-22192 and docket HHS-OASH-2026-0496, with an invitation for written comments through regulations.gov. The underlying policy and its appendices are posted on the HHS website.

The policy applies to six peptide bulk drug substances listed in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The stated reason for the policy is that the 503A bulk drug substances list is still being developed through rulemaking, and HHS chose to describe an interim position rather than leave the question open while that process runs.

Appendix B is the technical half of the document. For each substance it fixes the chemical identity that the policy is talking about, including salt form, molecular formula, molecular weight and amino acid sequence, and it limits the routes of administration that fall within scope. For Semax, Appendix B identifies the free base form, with molecular formula C₃₇H₅₁N₉O₁₀S, a molecular weight of 813.9 g/mol, and the sequence H-Met-Glu-His-Phe-Pro-Gly-Pro-OH. The route described as within scope is intranasal use. Notably, the policy names acetate salts for the other five peptides and the free base for Semax, so the salt form is a defining element of the scope rather than a detail buried in a certificate footnote.

The duration is tied to the rulemaking. For each substance, the position stays in place until a final rule addresses whether that substance is included on, or excluded from, the 503A bulks list. That makes the current situation a waypoint rather than a settled destination.

Does the policy require a prescription for a named patient?

Yes, and this is the first practical gate. The policy describes compounding pursuant to a valid prescription for an identified individual patient. That is the ordinary architecture of section 503A compounding: a specific prescriber, a specific patient, and a prescription that exists before the product is prepared. Preparing stock to sit on a shelf for whoever asks next does not match the description.

The second gate is composition. Under the policy, a compounded product may contain only one active ingredient, and that ingredient must be one of the six substances in Appendix A. The practical consequence is blunt: blends are outside the policy. A product that combines Semax with another peptide, whether that second peptide is on the Appendix A list or not, does not meet the single active ingredient condition. The multi-peptide formulations that circulate widely in the research chemical market have no place inside this framework.

The third gate is the route. Appendix B ties each substance to defined routes of administration, and for Semax free base the route described is intranasal. A preparation intended for a different route is not the thing the policy describes.

These three conditions interact. A valid prescription for a blend is still a blend. A single ingredient product prepared without a patient-specific prescription is still outside the policy. HHS framed its statement as applying when all of the described circumstances are met, not when most of them are, so each condition is load-bearing. Clinicians and pharmacists assessing their own exposure should read the policy text itself rather than any summary, including this one.

Where must the starting material come from?

The sourcing conditions are the most demanding part of the document, and they are where a great deal of currently available material would fail.

The policy describes the original manufacturer of the bulk drug substance as a facility registered with FDA under section 510 of the Federal Food, Drug, and Cosmetic Act, operating in compliance with current good manufacturing practice (CGMP) requirements, and whose physical manufacturing location is identified on the certificate of analysis supplied to the compounder. The emphasis on the original manufacturer matters: a certificate issued by a reseller, a broker, or a repackager that obscures where the material was actually made does not satisfy a condition written around the manufacturing site itself.

The certificate of analysis must then match the attributes that Appendix B sets out for the substance in question. Appendix B defines the identity being tested against, including the salt form or free base, the molecular formula, the molecular weight and the sequence, and the testing is expected to cover the quality attributes relevant to an injectable or mucosal drug substance: identity, assay and purity, impurities, endotoxins, heavy metals and microbiological quality. A lot-specific certificate is the unit of proof, not a generic specification sheet for the product line.

For a patient, none of this is visible from the outside. A pharmacy either holds the documentation or it does not. That is why the questions at the end of this article focus on documentation rather than on claims. Quality variability in peptide material sold outside regulated channels is a long-standing concern and is discussed further in our overview of peptide safety.

What must be reported and what must the label say?

Two conditions turn the arrangement into something that can be observed after the fact, which is what makes the policy revisable rather than open-ended.

The first is reporting. Compounders operating under the policy are expected to report serious adverse events and product quality problems to FDA through the MedWatch program, and to the relevant state authorities where the products are compounded and where they are sent, if those differ. MedWatch is FDA's program for reporting serious reactions, product quality problems, product use errors and suspected counterfeits involving human medical products. Health professionals use Form FDA 3500 and consumers use Form 3500B, with online submission available. Because Semax has not gone through the premarket evaluation that generates a safety database, post-market reporting is effectively the only systematic signal available to regulators.

The second is labeling. The policy requires the product to carry the statement "This is a compounded drug product. Not for resale." Two separate messages are packed into that sentence. The first tells the recipient that what they are holding was prepared by a pharmacy for a named patient and was not evaluated and approved by FDA. The second closes the loop on redistribution: a product compounded for one identified patient is not inventory to be passed along, resold, or redistributed.

If you are handed a product with no such statement on the label, that absence is informative on its own. It does not prove where the product came from, but it does mean the product is not labeled the way the policy describes. Any decision about using an unapproved product should be made with a licensed clinician who knows your medical history.

Why does the text mention only a 510(k) cleared syringe?

The policy addresses the physical article that ships with the compounded product. The device co-packaged with, or containing, the compounded drug is described as a syringe cleared under section 510(k), meaning a device that has been through FDA's premarket notification pathway. That is the single device the policy contemplates.

Read plainly, this has a consequence worth stating carefully: a pen or an auto-injector is not a 510(k) cleared syringe, so a product supplied in or with such a device does not match the condition as written. Pre-filled pens have become a common presentation in the wider peptide market, and on the face of the text they fall outside what HHS described.

Here is where precision matters more than inference. The policy names a syringe as the device co-packaged with or containing the compounded drug. It does not provide further specification regarding a nasal delivery device, even though Appendix B describes intranasal use as the route within scope for Semax free base. We are reporting what the text does and does not say. We are not going to fill that gap with speculation about what a nasal spray device would need to satisfy, because the document, as published, does not address it.

If you are a pharmacist weighing how to dispense within the policy, that silence is itself the finding, and it is a reasonable subject for a written comment to the docket or for a question to your state board of pharmacy. If you are a patient, it is a reasonable question to put to the pharmacy preparing the product.

Is this an approval or a place on the 503A list?

Neither, and HHS says so directly. The policy does not approve any peptide and does not add any peptide to the 503A bulk drug substances list. Products compounded under it remain unapproved drugs. The document states that it creates no rights for any person and is not binding on HHS or the public.

It is also explicitly temporary. For each substance, the position holds until a final rule determines whether that substance is included on the 503A bulks list. A final rule could go either way. If a substance is ultimately not listed, the interim position for that substance ends.

HHS also reserved the ability to revisit the policy, in whole or in part, if a safety signal or a product quality issue emerges. That is not boilerplate in this context. It is the mechanism that connects the MedWatch reporting condition to the survival of the policy itself, and it means the current situation can change without waiting for the rulemaking to finish.

One further point belongs in any honest account of this document. For these substances, the record reflects that FDA's Center for Drug Evaluation and Research had recommended against adding them to the 503A bulks list, while the Pharmacy Compounding Advisory Committee had voted in favor. HHS proceeded with an enforcement discretion policy notwithstanding the CDER recommendation. Readers who take regulatory signals seriously should weigh that: the agency component that reviews drug substances on the merits did not recommend listing. Absence of enforcement is not evidence of efficacy or of safety.

Who and what falls outside the policy?

The boundaries are as important as the contents, and three of them are explicit.

Research use only products are not covered. Material sold as "for research use only" or "not for human consumption" sits entirely outside this framework, and nothing in the policy legitimizes it. HHS went further and framed one purpose of the policy as discouraging the continued, widespread use of research use only peptides supplied by foreign manufacturers that pose a safety risk to United States patients. In other words, the policy is positioned as an alternative to that market, not an endorsement of it. Anyone reading the announcement as a green light for research chemical channels has read it backwards.

503B outsourcing facilities are not covered. The policy is written around section 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians. Outsourcing facilities registered under section 503B, which operate under a different statutory regime and generally supply office stock rather than patient-specific prescriptions, are outside its scope.

Nothing changes outside the United States. This is a United States federal policy addressing United States federal enforcement under the Federal Food, Drug, and Cosmetic Act. It has no bearing on the regulatory status of Semax in the European Union, the United Kingdom, Canada, Australia, or anywhere else, and it does not create an import pathway. National rules on unapproved medicines, personal importation and prescription requirements continue to apply on their own terms. Our overview of peptide legal status by jurisdiction covers that broader landscape.

State law is a further layer even within the United States. State boards of pharmacy and state medical boards retain their own authority, and a federal statement of enforcement intent does not override state requirements.

What should you ask a clinician and a pharmacy?

If you are considering raising Semax with a healthcare professional, the useful questions are factual and verifiable. They are not a substitute for clinical judgment, and nothing here should be read as encouragement to pursue an unapproved product.

Questions for a clinician:

  • Semax is not FDA approved. What is the clinical reasoning for considering an unapproved product in my specific case, and what approved options exist?
  • What is the current published human evidence base, and what are its limits in size, duration and population?
  • What are the known and unknown risks, including interactions with my current medications and conditions?
  • How would we monitor me, and at what point would we stop?
  • Would you be the prescriber of record, and how does my state regulate this?

Questions for a pharmacy:

  • Are you a state-licensed 503A pharmacy, and are you compounding within the HHS policy of October 28, 2026?
  • Can you confirm the product contains a single active ingredient and is not a blend?
  • Who is the original manufacturer of the bulk drug substance, is that facility registered with FDA, and does the certificate of analysis identify its physical location?
  • Can I see the lot-specific certificate of analysis, and does it cover the attributes set out in Appendix B?
  • Does the label carry the statement "This is a compounded drug product. Not for resale."?
  • How do you report serious adverse events and product quality problems to MedWatch and to the state?

A pharmacy operating inside the policy should be able to answer each of these without hesitation. Vagueness about the manufacturer, refusal to show a lot-specific certificate, or a product that is a blend are all signals that the preparation does not match what HHS described.

Medical disclaimer: this article is for educational purposes only. It is not medical advice, it does not recommend using Semax, and it contains no guidance on administration. Semax is not approved by the FDA or the EMA. Consult a qualified healthcare professional before making any health decision.

Recommended products

Research peptides selected for quality and purity:

Test your knowledge

Quick quiz · 6 questions

Frequently Asked Questions

Can a doctor in the United States legally write a Semax prescription in 2026?
Semax is not an FDA approved drug, so no prescriber can prescribe it as an approved medicine. What exists since October 28, 2026 is an HHS enforcement discretion policy stating that HHS does not intend to take action against a state-licensed pharmacy, a federal facility, or a licensed physician who compounds Semax free base for intranasal use when every condition in the policy is met, including a valid prescription for an identified individual patient. That is a statement about enforcement intent, not an authorization. State boards of pharmacy and state medical boards also retain their own authority, so the answer can differ by state.
Does the HHS policy mean Semax is now legal in the United States?
No. The policy expressly does not approve any peptide and does not add any peptide to the 503A bulk drug substances list. Products compounded under it remain unapproved drugs. HHS states the document creates no rights, is not binding on HHS or the public, and is temporary. It remains in effect for each substance only until a final rule decides whether that substance belongs on the 503A list, and HHS reserved the ability to revisit it if a safety signal or a product quality issue emerges.
Does the policy cover Semax combined with other peptides?
No. One of the conditions is that the compounded product contain only a single active ingredient, which must be one of the six substances listed in Appendix A of the policy. A product combining Semax with another peptide, including another peptide on that same list, does not satisfy the single active ingredient condition and therefore falls outside the policy.
Does the policy allow a pen or auto-injector to be supplied with the product?
The policy describes a syringe cleared under section 510(k) as the device co-packaged with or containing the compounded drug. A pen or auto-injector is not a 510(k) cleared syringe, so on a plain reading of the text such a presentation falls outside the policy. The text names a syringe as the only device packaged with the product and does not provide further specification regarding a nasal delivery device, which is worth noting precisely because Appendix B describes intranasal use as the route within scope for Semax free base.
Are research use only Semax products covered by this policy?
No. Material sold as research use only sits entirely outside the framework, and the policy does not legitimize it. HHS framed one purpose of the policy as discouraging the continued, widespread use of research use only peptides supplied by foreign manufacturers that it describes as posing a safety risk to United States patients. The policy also does not extend to 503B outsourcing facilities, which operate under a separate statutory regime.
Does this change anything for Semax outside the United States?
No. The policy is a United States federal statement about enforcement under the Federal Food, Drug, and Cosmetic Act. It has no effect on the regulatory status of Semax in the European Union, the United Kingdom, Canada, Australia or any other country, and it does not create an import pathway. National rules on unapproved medicines and prescription requirements continue to apply independently.

Sources

  1. U.S. Department of Health and Human Services (2026). HHS 503A Peptide Enforcement Discretion Policy, Appendix B: Peptide Identities and Justifications. HHS.gov. (hhs.gov)
  2. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket HHS-OASH-2026-0496). Federal Register, Vol. 91, No. 209. (federalregister.gov)
  3. U.S. Government Publishing Office (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Notices, 68526. Federal Register, Vol. 91, No. 209 (October 30, 2026). (govinfo.gov)
  4. U.S. Food and Drug Administration (2026). MedWatch: Reporting Serious Problems to FDA. FDA.gov. (fda.gov)
  5. U.S. Food and Drug Administration (2026). MedWatch Forms for FDA Safety Reporting (Forms 3500, 3500A, 3500B). FDA.gov. (fda.gov)
  6. Holland & Knight LLP (2026). HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides. Holland & Knight Insights. (hklaw.com)
  7. Arnold & Porter (2026). HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending. Arnold & Porter Advisories. (arnoldporter.com)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer